Amarin completes enrollment for Ph III Miraxion HD trial
UK-based neuroscience company Amarin says it has enrolled 240 patients into a Phase III trial of Miraxion (eicosapentaenoic acid), it developmental treatment for the neurodegenerative condition Huntington's disease. The product has been granted Orphan Drug designation in both the USA and Europe for the treatment of HD, in addition to being earmarked for fast-track review by the US Food and Drug Administration.
The study, which is being conducted at 27 European neurology centers, is designed to compare the effects of the drug with placebo on the condition in terms of total motor score, as laid out on the United Huntington's Disease Rating Scale.
Rick Stewart, Amarin's chief executive, said: "the swift completion of target patient enrollment in our European Phase III trial ahead of schedule marks an important milestone for our company."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze